USFDA8 May 2024, 07:41 pm
USFDA Issues observation during Routine Inspection of CIPLA LTD.'s Kurkumbh Facility
AI Summary
The United States Food and Drug Administration (USFDA) conducted a routine Current Good Manufacturing Practices (CGMP) inspection at CIPLA LTD.'s manufacturing facility in Kurkumbh, Maharashtra, India from April 29, 2024 to May 8, 2024. The inspection resulted in one observation which the company intends to address comprehensively within the given timeframe.
Key Highlights
- USFDA conducted a routine inspection of CIPLA LTD.'s Kurkumbh facility
- One observation noted during the inspection
- Company committed to addressing the observation within stipulated time